Whether you think PANS/PANDAS is a Rare Disease or actually just rarely diagnosed, it is a day to educate people about PANS/PANDAS. The main objective of Rare Disease Day is to raise awareness...
Dritain Agalliu, PhD, is co-organizing the virtual Brain Barriers research conference in Cold Spring Harbor, NY on April 7 - 9, 2021. Abstract deadline is January 29, 2021. The conference is open...
This presentation provides an overview of how PANS/PANDAS impacts classroom functioning across physical, socio-emotional, academic, and behavioral domains. Presenters will describe strategies and...
New clinical trial on the use of Aleve for symptoms of OCD in PANDAS patients. Kyle Williams, MD from MGH is the lead investigator on this double-blind, randomized, placebo-controlled trial. Details...
On behalf of ASPIRE, thank you for your ongoing support, and we hope you have a happy and healthy New...
Editor’s Note:
Genes, Cells, and Neural Circuits Relevant to OCD and Autism Spectrum Disorder
Ned H. Kalin, M.D.
Published Online:1 Jan 2021 DOI 10.1176/appi.ajp.2020.20111605
“These cross-species translational data are potentially exciting and serve to focus the search for the pathophysiology of PANDAS toward a specific class of inter-neurons within the striatum that are known to fine tune and regulate striatal output via their influences on the abundant medium spiny GABAergic neurons that project to effector sites. Because of the similarities between PANDAS and bonafide OCD, these studies raise the possibility that striatal cholinergic interneurons are mechanistically involved in the pathophysiology of childhood OCD. In his editorial (9), Dr. Steve Hyman from Harvard University critically appraises this study and suggests that, in addition to the mechanism suggested by the findings in this article, other immune-related molecular pathways may also be important.”
Predictors and Prospective Course of PANS: A Pilot Study Using Electronic Platforms for Data Collection
Conclusion: Our study highlights the utility of electronic methods for tracking longitudinal symptoms in children with PANS and suggests that particular baseline characteristics (e.g., delay in identification and treatment of PANS, greater caregiver burden) may be indicative of a differential trajectory of PANS course, with more severe symptoms over the short term. clinicaltrials.gov NCT04382716.
Michael McCartney serves as ASPIRE’s Vice President and focuses on organizational strategy, community engagement, communications, and...
Despite the challenges of 2020, we are proud to report that the ASPIRE community continues to grow in size, support, and strength. We are grateful to all of you for your contributions: the...
"The goal of this project is to challenge the narrative about who in this country is on the front lines of the fight against COVID 19 by honoring women of color physicians with portraits reflecting...
“A small number of Covid patients who had never experienced mental health problems are developing severe psychotic symptoms weeks after contracting the...
Recent Breakthroughs in PANDAS Research Recent Breakthroughs in PANS/PANDAS Research with Kyle Williams, MD, director of the Pediatric Neuropsychiatry and Immunology Program, discussed new findings...